Quantcast

Latest Morphotek Inc. Stories

2011-06-28 08:00:00

EXTON, Pa., June 28, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC).

2011-06-27 08:00:00

EXTON, Pa., June 27, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has successfully completed a campaign to collect 8,792 pounds of food from its employees, more than 5 times as much as it collected last year.

2011-06-08 08:00:00

EXTON, Pa., June 8, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designations to two of its investigational cancer drugs, MORAb-004 for the treatment of soft tissue sarcoma and MORAb-066 for the treatment of pancreatic cancer.

2011-06-02 08:00:00

EXTON, Pa., June 2, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the treatment of metastatic melanoma.

2011-04-12 08:00:00

EXTON, Pa., April 12, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the company has received a grant of approximately $947,000 from the United States Department of Defense (DOD) to support the continued development of therapeutic monoclonal antibodies (mAbs) capable of neutralizing the toxic effects of botulinum neurotoxins (BOTN).

2011-04-06 08:00:00

EXTON, Pa., April 6, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it was recently awarded the Beacon Award from CancerCare, a national support services organization for people affected by cancer, for its support of CancerCare's educational programs for people facing lung and ovarian cancers.

2011-04-04 20:30:00

EXTON, Pa., April 4, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. (TMI) for an undisclosed upfront payment and future development milestones.


Word of the Day
edulcoration
  • The act of sweetening by admixture of some saccharine substance.
The word 'edulcoration' comes from a Latin word meaning 'making sweet'.